Literature DB >> 8352752

N.m.r. and molecular-modelling studies of the solution conformation of heparin.

B Mulloy1, M J Forster, C Jones, D B Davies.   

Abstract

The solution conformations of heparin and de-N-sulphated, re-N-acetylated heparin have been determined by a combination of n.m.r. spectroscopic and molecular-modelling techniques. The 1H- and 13C-n.m.r. spectra of these polysaccharides have been assigned. Observed 1H-1H nuclear Overhauser enhancements (n.O.e.s) have been simulated using the program NOEMOL [Forster, Jones and Mulloy (1989) J. Mol. Graph. 7, 196-201] for molecular models derived from conformational-energy calculations; correlation times for the simulations were chosen to fit experimentally determined 13C spin-lattice relaxation times. In order to achieve good agreement between calculated and observed 1H-1H n.O.e.s it was necessary to assume that the reorientational motion of the polysaccharide molecules was not isotropic, but was that of a symmetric top. The resulting model of heparin in solution is similar to that determined in the fibrous state by X-ray-diffraction techniques [Nieduszynski, Gardner and Atkins (1977) Am. Chem. Soc. Symp. Ser. 48, 73-80].

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8352752      PMCID: PMC1134446          DOI: 10.1042/bj2930849

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  23 in total

1.  Crystalline structure of heparin.

Authors:  E D Atkins; I A Nieduszynski
Journal:  Adv Exp Med Biol       Date:  1975       Impact factor: 2.622

2.  Molecular modeling of protein-glycosaminoglycan interactions.

Authors:  A D Cardin; H J Weintraub
Journal:  Arteriosclerosis       Date:  1989 Jan-Feb

3.  Heparin potentiates the action of acidic fibroblast growth factor by prolonging its biological half-life.

Authors:  D H Damon; R R Lobb; P A D'Amore; J A Wagner
Journal:  J Cell Physiol       Date:  1989-02       Impact factor: 6.384

4.  Binding of heparin to human platelet factor 4.

Authors:  S W Cowan; E N Bakshi; K J Machin; N W Isaacs
Journal:  Biochem J       Date:  1986-03-01       Impact factor: 3.857

5.  Polysaccharide-polypeptide systems as models for heparin interactions.

Authors:  J Blackwell; K P Schodt; R A Gelman
Journal:  Fed Proc       Date:  1977-01

6.  Conformations of blood group H-active oligosaccharides of ovarian cyst mucins.

Authors:  B N Rao; V K Dua; C A Bush
Journal:  Biopolymers       Date:  1985-12       Impact factor: 2.505

7.  Conformational equilibria of alpha-L-iduronate residues in disaccharides derived from heparin.

Authors:  P N Sanderson; T N Huckerby; I A Nieduszynski
Journal:  Biochem J       Date:  1987-04-01       Impact factor: 3.857

8.  The Second International Standard for heparin.

Authors:  D R BANGHAM; M V MUSSETT
Journal:  Bull World Health Organ       Date:  1959       Impact factor: 9.408

9.  Heparin protects basic and acidic FGF from inactivation.

Authors:  D Gospodarowicz; J Cheng
Journal:  J Cell Physiol       Date:  1986-09       Impact factor: 6.384

10.  Dermatan sulfate: molecular conformations and interactions in the condensed state.

Authors:  A K Mitra; S Arnott; E D Atkins; D H Isaac
Journal:  J Mol Biol       Date:  1983-10-05       Impact factor: 5.469

View more
  108 in total

1.  Structural interactions of fibroblast growth factor receptor with its ligands.

Authors:  D J Stauber; A D DiGabriele; W A Hendrickson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  Crystal structure of a heparin- and integrin-binding segment of human fibronectin.

Authors:  A Sharma; J A Askari; M J Humphries; E Y Jones; D I Stuart
Journal:  EMBO J       Date:  1999-03-15       Impact factor: 11.598

3.  Crystal structure of the OpcA integral membrane adhesin from Neisseria meningitidis.

Authors:  Stephen M Prince; Mark Achtman; Jeremy P Derrick
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

Review 4.  Heparan sulfate: growth control with a restricted sequence menu.

Authors:  J T Gallagher
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

5.  Conformation of heparin studied with macromolecular hydrodynamic methods and X-ray scattering.

Authors:  Georges Pavlov; Stéphanie Finet; Karine Tatarenko; Evgueniya Korneeva; Christine Ebel
Journal:  Eur Biophys J       Date:  2003-07-03       Impact factor: 1.733

6.  Finding a needle in a haystack: development of a combinatorial virtual screening approach for identifying high specificity heparin/heparan sulfate sequence(s).

Authors:  Arjun Raghuraman; Philip D Mosier; Umesh R Desai
Journal:  J Med Chem       Date:  2006-06-15       Impact factor: 7.446

7.  Conformational transitions induced in heparin octasaccharides by binding with antithrombin III.

Authors:  Marco Guerrini; Sara Guglieri; Daniela Beccati; Giangiacomo Torri; Christian Viskov; Pierre Mourier
Journal:  Biochem J       Date:  2006-10-15       Impact factor: 3.857

8.  Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation.

Authors:  Vaclav Veverka; Alistair J Henry; Patrick M Slocombe; Andrew Ventom; Barbara Mulloy; Frederick W Muskett; Mariusz Muzylak; Kevin Greenslade; Adrian Moore; Li Zhang; Jianhua Gong; Xueming Qian; Chris Paszty; Richard J Taylor; Martyn K Robinson; Mark D Carr
Journal:  J Biol Chem       Date:  2009-02-10       Impact factor: 5.157

9.  Identification of a heparin-binding motif on adeno-associated virus type 2 capsids.

Authors:  A Kern; K Schmidt; C Leder; O J Müller; C E Wobus; K Bettinger; C W Von der Lieth; J A King; J A Kleinschmidt
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Heparan sulfate phage display antibodies identify distinct epitopes with complex binding characteristics: insights into protein binding specificities.

Authors:  Sophie M Thompson; David G Fernig; Edwin C Jesudason; Paul D Losty; Els M A van de Westerlo; Toin H van Kuppevelt; Jeremy E Turnbull
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.